« Return to News | Clinical Intelligence

Arena posts phase I trial results

Wednesday, July 13, 2011 10:17 AM

Arena Pharmaceuticals has announced results from a phase I clinical trial of APD811, an orally bioavailable agonist of the prostacyclin receptor intended for the treatment of pulmonary arterial hypertension, or PAH.

The randomized, double-blind, placebo-controlled trial evaluated the safety, tolerability and pharmacokinetics of 0.03mg, 0.05mg, 0.1mg and 0.2mg single doses of APD811. The trial evaluated 32 healthy volunteers in four cohorts of eight participants each—six randomized to APD811 and two to placebo. APD811 was rapidly absorbed and demonstrated dose-proportional pharmacokinetic exposure over the tested dose range. The terminal half-life was approximately 20 hours.

The most frequent treatment-emergent adverse events were headache, vomiting, nausea, jaw pain and flushing. Dose-limiting adverse events of nausea and vomiting occurred at the 0.2mg dose. As compared to placebo, heart rate trended higher at the 0.05mg, 0.1mg and 0.2mg doses and the corrected QT (QTc) interval trended higher at the 0.1mg and 0.2mg doses. Arena believes the QTc observation is not supported by pre-clinical data and will further evaluate this in future studies. No serious adverse events were reported.

"We are encouraged by the results of this early-stage clinical trial that suggest APD811 has the potential for once-daily oral dosing, and our next step will be to evaluate the safety, tolerability and pharmacokinetics of multiple dosing and the optimal titration schedule in a phase Ib trial," said William R. Shanahan, M.D., Arena's senior vice president and Chief Medical Officer.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.